Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Futibatinib + Binimetinib in Advanced KRAS Mutant Cancer
NCT04965818Phase 1Terminated
- Sponsor
- Taiho Oncology
- Start
- Sep 2021
- Primary completion
- Jun 2023
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of futibatinib in solid tumor and non-small cell lung cancer (NSCLC), sponsored by Taiho Oncology. Primary endpoints: Recommended Phase 2 Dose at 12 months and Objective Response Rate at 24 months. Started Sep 2021; status: terminated.
02
Drugs
futibatinib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04965818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965818.